Literature DB >> 8488608

Staging of early prostate cancer: a proposed tumor volume-based prognostic index.

D G Bostwick1, S D Graham, P Napalkov, P A Abrahamsson, P A di Sant'agnese, F Algaba, P A Hoisaeter, F Lee, P Littrup, F K Mostofi.   

Abstract

Current staging of early prostate cancer separates patients into two groups: those with palpable and non-palpable tumors. Such staging relies on digital rectal examination in making this separation, despite the low sensitivity, low specificity, and low positive predictive value of this method. As an alternative, tumor volume may be useful for staging because of its powerful prognostic ability and its potential to be assessed clinically due to recent advances in imaging techniques such as transrectal ultrasound. In this study, we evaluate the utility of tumor volume in predicting progression of early prostate cancer based on the composite published evidence from nine pathologic studies of serially-sectioned prostates. Logistic regression revealed that tumor volume was a good positive predictor of all measures of tumor progression. There was a 10 percent probability of capsular invasion in tumors measuring about 0.5 cm3; 10 percent probability of seminal vesicle invasion in tumors measuring about 4.0 cm3; and 10 percent probability of metastases in tumors measuring about 5.0 cm3. These composite results suggest that tumor volume is a significant predictor of cancer progression. A volume-based prognostic index is proposed as an adjunct to staging for early prostate cancer.

Entities:  

Mesh:

Year:  1993        PMID: 8488608     DOI: 10.1016/0090-4295(93)90497-x

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  31 in total

Review 1.  Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer.

Authors:  J Kurhanewicz; D B Vigneron; S J Nelson
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

2.  Use of tumor dynamics to clarify the observed variability among biochemical recurrence nomograms for prostate cancer.

Authors:  Guy Dimonte; E J Bergstralh; M E Bolander; R J Karnes; D J Tindall
Journal:  Prostate       Date:  2011-05-31       Impact factor: 4.104

Review 3.  Methods for volume assessment of prostate cancer.

Authors:  Heinz-Peter Schlemmer; Stefan Corvin
Journal:  Eur Radiol       Date:  2004-02-06       Impact factor: 5.315

4.  Tissue shrinkage after fixation with formalin injection of prostatectomy specimens.

Authors:  Sara Jonmarker; Alexander Valdman; Anna Lindberg; Magnus Hellström; Lars Egevad
Journal:  Virchows Arch       Date:  2006-08-15       Impact factor: 4.064

5.  Using biopsy to detect prostate cancer.

Authors:  Shahrokh F Shariat; Claus G Roehrborn
Journal:  Rev Urol       Date:  2008

6.  Predicting the risk of non-organ-confined prostate cancer when perineural invasion is found on biopsy.

Authors:  Michael A Gorin; Heather J Chalfin; Jonathan I Epstein; Zhaoyong Feng; Alan W Partin; Bruce J Trock
Journal:  Urology       Date:  2014-03-19       Impact factor: 2.649

Review 7.  Primary staging of prostate cancer.

Authors:  G J Jager; J O Barentz; E T Ruijter; J J de la Rosette; G O Oosterhof
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

Review 8.  Evaluating radical prostatectomy specimens: therapeutic and prognostic importance.

Authors:  D G Bostwick; R Montironi
Journal:  Virchows Arch       Date:  1997-01       Impact factor: 4.064

9.  Evaluating the size criterion for PI-RADSv2 category 5 upgrade: is 15 mm the best threshold?

Authors:  Julie Y An; Stephanie A Harmon; Sherif Mehralivand; Marcin Czarniecki; Clayton P Smith; Julie A Peretti; Bradford J Wood; Peter A Pinto; Peter L Choyke; Joanna H Shih; Baris Turkbey
Journal:  Abdom Radiol (NY)       Date:  2018-12

10.  Development and Evaluation of an Actuated MRI-Compatible Robotic System for MRI-Guided Prostate Intervention.

Authors:  Axel Krieger; Sang-Eun Song; Nathan B Cho; Iulian Iordachita; Peter Guion; Gabor Fichtinger; Louis L Whitcomb
Journal:  IEEE ASME Trans Mechatron       Date:  2011-10-17       Impact factor: 5.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.